Search clinical trials for: Formoterol/Fluticasone

Total 1067 results

Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

COPD

Turkey
Imperial College London
AstraZeneca

Completed

Effect of Symbicort on GR Localisation in Asthma

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
AstraZeneca

Completed

Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations

Asthma

Netherlands
GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Asthma

United States, Canada, Russian Federation, Mexico, Australia, Ukraine
GlaxoSmithKline

Completed

Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications

Asthma

Netherlands
Leiden University Medical Center
GlaxoSmithKline; Academisch Ziekenhuis Groningen; Netherlands Organisation for... and other collaborators

Terminated

Modification Of Disease Outcome In COPD

Chronic Obstructive Pulmonary Disease

Netherlands
University of Copenhagen

Unknown

Beta2-adrenergic System and Training

Healthy
Novartis Pharmaceuticals

Withdrawn

Efficacy of Indacaterol 150 µg Versus Formoterol

Chronic Obstructive Pulmonary Disease (COPD)
Chiesi Farmaceutici S.p.A.

Completed

Formoterol-HFA 3-month Study in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Poland
Sanofi
Regeneron Pharmaceuticals

Completed

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

Asthma

Ukraine, United States, Argentina, Chile, Mexico, Poland, Russian Federation, Turkey
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus

Asthma

Finland
GlaxoSmithKline

Completed

Fall Epidemic Viral Pediatric Study

Asthma

United States
GlaxoSmithKline

Completed

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Pulmonary Disease, Chronic Obstructive

United States
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

Asthma

Finland
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
Chiesi Farmaceutici S.p.A.
University of Pisa; Fondazione Don Carlo Gnocchi Onlus; Universita degli Studi... and other collaborators

Completed

Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Italy
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

Type 1 Diabetes

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)

Chronic Obstructive Pulmonary Disease (COPD)
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

Asthma

Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, Sweden, United Kingdom
Ache Laboratorios Farmaceuticos S.A.

Completed

Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma (Ach-ALN)

Asthma
Orion Corporation, Orion Pharma

Completed

Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Asthma

Finland
Orion Corporation, Orion Pharma

Completed

Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics (KINECO)

Asthma

United Kingdom
AstraZeneca

Completed

An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients

Asthma | Airway Inflammation

United Kingdom
Shanghai Pulmonary Hospital, Shanghai, China

Unknown

Comparisons of Inhaled LAMA or LAMA+LABA or ICS+LABA for COPD With Bronchiectasis

Bronchiectasis | COPD

China
Merck Sharp & Dohme LLC
Novartis; Integrated Therapeutics Group

Completed

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

Pulmonary Disease, Chronic Obstructive
Adare Pharmaceuticals, Inc.

Completed

Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) (FLUTE)

Eosinophilic Esophagitis

Spain, United States, Belgium, Switzerland, Germany, Canada
GlaxoSmithKline

Completed

A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis

Rhinitis, Allergic, Perennial

Thailand
Dey

Completed

12-Week Study in Adult Subjects With Asthma

Asthma

United States
GlaxoSmithKline

Completed

Regulatory AVAMYS Nasal Spray PMS

Rhinitis, Allergic, Perennial and Seasonal

Korea, Republic of
Ellodi Pharmaceuticals, LP

Available

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

Eosinophilic Esophagitis

United States
Ellodi Pharmaceuticals, LP

Completed

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial (FLUTEEN)

Eosinophilic Esophagitis

Australia, United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Rhinitis, Allergic, Perennial

United States
Rush University Medical Center
GlaxoSmithKline

Completed

Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms

Allergic Conjunctivitis to Tree Pollen or Grass Pollen

United States
Fraunhofer-Institute of Toxicology and Experimental...

Completed

Suitability of a Low Dose Lipopolysaccharide (LPS) Inhalation as a Challenge Model

Healthy

Germany
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

COPD
GlaxoSmithKline

Completed

Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate

Asthma

New Zealand
Netherlands Institute for Pigment Disorders

Withdrawn

Fractional Laser in Combination With UVB Therapy in Vitiligo Patients

Vitiligo

Netherlands
AstraZeneca

Completed

Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

Japan
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Individualized Therapy For Asthma in Toddlers (INFANT)

Asthma | Wheezing

United States
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects

Asthma

United Kingdom, Germany
GlaxoSmithKline

Completed

Viapaed Study In Children And Adolescents With Asthma

Asthma

Germany
University of Chicago

Unknown

Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis

Allergic Rhinitis

United States
Merck Sharp & Dohme LLC

Completed

Study of Biomarkers of Airway Inflammation (0000-128)

Airway Inflammation
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders

3

Subscribe